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The asymmetric unit of the title structure is shown in the gure. Tables 1-3 contain details of the methods used and a list of the atoms including atomic coordinates and displacement parameters. 
Experimental details
The hydrogen atoms were placed on calculated positions with the help of the SHELX program (AFIX 43 or 137 option) [14] . The atoms Cl1/Cl1A and F1/F1A are disordered over two positions with occupancy factors of 0.768(6) (Cl1, F1) and 0.232(6) (Cl1A, F1A).
Discussion
Pyrazolone derivatives as phenazone, metamizole, aminophenazone and propyphenazone have long been utilized as analgesic, anti-in ammatory and antipyretic drugs [1] [2] [3] [4] [5] . In addition, several pyrazolone derivatives were reported to exhibit marked antimicrobial [6] [7] [8] , herbicidal [9] and anti-HIV [10] activities. Moreover, the pyrazolone derivative edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; MCI-186) was discovered as a radical scavenger that interrupt the peroxidative chain reactions and membrane disintegrations associated with cerebral ischemia [11, 12] . In the present study, we describes the synthesis, spectroscopy and crystal structure of the title pyrazolone Schi 's base as a precursor to potential bioactive agents. In the title compound C 18 H15ClFN 3 O, the asymmetric unit contain two independent molecules. The pyrazol-5-one ring (N1/N2/C7/C8/C9) makes the dihedral angles of 59.84(2)°a nd 84.16(5)°with the phenyl ring (C1-C6) in molecules A and B, respectively. The packing structure shows no classical hydrogen bonds but at least one non-classical hydrogen bond (C17A-H17B· · · O1A with symmetry code: −x+2, −y+1, −z+1) is present.
